Articles tagged with Vaccine Target
Cedars-Sinai OB-GYN experts present research on improving preeclampsia detection through AI-powered analysis of electronic health records. They also explore the relationship between incomplete information on vaccine side effects and COVID-19 vaccine hesitancy, highlighting the need for targeted preventive therapies. Furthermore, the te...
A new genomics study has helped guide the development of vaccines against Shigella, a leading cause of severe diarrhoea in children. The research revealed the extent of genomic diversity among Shigella species, highlighting challenges to current vaccine approaches.
Researchers are working tirelessly to develop vaccines against the Omicron variant, a crucial step in combating the pandemic. By understanding the biology of Omicron, scientists hope to create effective treatments and boosters to protect against future pandemics.
Researchers discovered nine genes in S. mansoni's autophagy pathway inhibited by the primate's immune system, preventing parasite multiplication and contaminating the host. The study suggests a potential novel therapy and vaccine against schistosomiasis.
Researchers identified 40 peptide pairs with potential cross-reactivity between BCG vaccination and SARS-CoV-2, offering a new strategy to complement existing COVID-19 vaccines. These peptides can induce T cell responses and INF-γ production, providing long-lasting immunity against viral infections.
A new study from USC researchers sheds light on COVID-19 vaccine inequities in California, revealing disparities in vaccination rates among vulnerable populations. The study suggests that targeted community outreach and improved vaccine access can help reduce these disparities.
Researchers found that even unrelated vaccines can provide cross-protection against multiple pathogens, reducing caseloads and hospital usage. Vaccinating vulnerable populations with other vaccines during the pandemic can have a substantial impact.
The Omicron variant is more transmissible than the Delta variant, spreading to individuals with two vaccine doses and previously infected individuals. A booster dose of Pfizer or AstraZeneca vaccine significantly increases antibody levels that can neutralize Omicron.
Researchers identified antibodies targeting conserved sites on the spike protein, showing promise against future variants. Antibodies from vaccinated individuals retained some activity, while those with prior infection had reduced effectiveness.
Researchers identify a previously overlooked site on the HA protein, known as the 'anchor epitope', which can neutralize a wide range of influenza strains. This discovery has significant implications for the development of universal influenza vaccines and antibody therapies.
Scientists identify a new site of vulnerability on the influenza virus called the anchor, which has potential to recognize broad variety of flu strains. The discovery paves way for rational vaccine design and could lead to improved universal flu vaccines.
Researchers found that mRNA vaccines were highly effective (86%) in preventing SARS-CoV-2-related deaths among vaccinated individuals, especially in the elderly population. However, vaccine effectiveness against infection was lower (69%) and decreased with increasing age and comorbidity burden.
Despite low vaccine uptake, West Africa needs to boost vaccination efforts to achieve population-level immunity. To reach 50%, 60%, and 70% coverage after 9, 12, and 18 months, vaccination speeds must increase by 4, 7, and 10 times the current pace.
Researchers at UCLA have identified rare T cells capable of targeting a protein found in SARS-CoV-2 and other coronaviruses. By adding a fragment of this protein to vaccines, they hope to create a longer-lasting immune response and increase protection against new variants. This breakthrough could lead to more effective COVID-19 vaccines.
Researchers found that a combination of natural infection and vaccination produces maximally potent antibodies against COVID-19. The study suggests that repeated exposures to the spike protein can improve the immune system's ability to produce high-quality antibodies against variants.
Researchers identify a molecular culprit for COVID-19's seasonal nature, finding a galectin-like structure on the spike protein that responds to external seasonal patterns. This discovery could help predict future mutations and potentially pave the way for new therapeutics or vaccines.
Research team discovered mRNA vaccines induce antibodies recognizing Spike and N protein fragments, potentially leading to misclassified breakthrough infections. The study suggests using multiple viral antigens for accurate detection of vaccine effectiveness.
A new study used machine learning to predict the zoonotic capacity of 5,400 mammal species, identifying those at high risk of transmitting SARS-CoV-2. The model, which combined data on biological traits with ACE2 receptor information, predicted 72% accuracy and identified numerous additional species with potential to transmit the virus.
Researchers have discovered a promising new treatment and vaccine for Alzheimer's disease by targeting the toxic form of amyloid beta protein. Both the antibody-based treatment and the protein-based vaccine reduced Alzheimer's symptoms in mouse models, offering hope for potential transformation in patient lives.
Researchers have discovered a new target for COVID-19 vaccines that could complement existing vaccines by inducing an immune response against 'replication proteins', essential for the viral cycle. The approach may lead to the creation of a pan-coronaviruses vaccine protecting against SARS-CoV-2 and other coronaviruses.
An updated vaccination strategy is credited with averting an outbreak of urban yellow fever in São Paulo State, according to research published in Scientific Reports. The study found that the virus spread rapidly, reaching cities never affected before, and that a high number of cases were reported in areas with low vaccination coverage.
A new study by CUNY SPH found that COVID-VAC scale can inform targeted interventions to increase vaccine uptake among hesitant groups. Key motivators for vaccination included protecting oneself and loved ones from COVID-19, with continued testing crucial in combating misconceptions.
Researchers at University of Queensland successfully protected mice from COVID-19 using a US-developed vaccine candidate delivered via a pocket-sized, pain-free applicator. The vaccine produced strong immune responses and neutralized multiple variants, including UK and South Africa variants.
The Delta variant is the most infectious known to date due to its ability to fuse with cells quickly and efficiently. Researchers found that Delta's spike protein has a unique property that accounts for its transmissibility, making it a favorable target for next-generation vaccines and treatments.
Researchers developed a device that uses light to manipulate and isolate individual viruses, enabling precise diagnosis, treatment, and study of viruses. The device has the potential to aid in vaccine development and research on SARS-CoV-2 virus, allowing for targeted analysis of specific virus mutants.
Researchers at Osaka University developed a vaccine that offers cross-protection against SARS coronaviruses by targeting the conserved core region of the spike protein receptor-binding domain. This approach has the potential to protect against future outbreaks, including those caused by novel viruses.
Patients with multiple myeloma often mount a poor antibody response to COVID-19 vaccines and have a weak T cell response, underscoring the need for booster vaccination and safety precautions. Researchers found that these patients are at high risk of severe COVID-19 infection.
Researchers developed a program to target vaccinations using digital contact tracing technology, which can almost halve the number of vaccines required to bring the pandemic under control. The new program prioritizes individuals with the most contacts for vaccinations while keeping personal data private.
Researchers discovered that RSV's NS1 protein alters immune gene expression to evade the immune response. The study provides crucial data for targeting NS1 in drug or vaccine development and may shed light on the link between RSV and asthma.
A study published in JAMA Oncology found that the type of cancer treatment affects the vaccine response, with chemotherapy resulting in lower antibody levels. Vaccination is still recommended for cancer patients, but optimal protection requires ongoing measures.
Pediatric transplant recipients have a more robust immune response to COVID-19 vaccines, achieving higher antibody levels after two doses compared to adult counterparts. This study suggests that the standard two-dose regimen may be safe and effective in pediatric transplant recipients.
Researchers developed an Internet information system, virusMED, to provide a comprehensive picture of viruses' most important regions. The database contains over 800 strains from 75 different families, including SARS-CoV-2, influenza, Ebola, and HIV-1, enabling scientists to respond quickly and effectively against the next pathogen.
Researchers identified five specific mutations prevalent in Delta Plus infections compared to Delta, highlighting the need for expanded antiviral tools. The findings provide clues on how the virus mutates and evade antibodies produced from previous COVID-19 infections or vaccinations.
Researchers developed a mathematical model to study the action of SARS-CoV-2, enabling the examination of individual virus particles and their spikes. This analysis can help fine-tune prevention and treatment by providing insights into viral load, spike distribution, and cell infection potential.
A team of researchers from IOCB Prague has discovered a new type of nanoparticles capable of safely transporting various types of nucleic acids used for therapeutic purposes into cells. The universal nature of their system sets it apart from existing solutions, allowing for efficient transport of mRNA and other RNA molecules into cells.
Increasing concerns about HPV vaccine safety among parents are linked to misinformation and a lack of understanding of the vaccine's benefits. Despite overwhelming scientific evidence supporting its safety, survey results indicate a growing number of parents are hesitant to vaccinate their children.
MIT researchers have found that vaccinating against certain cancer proteins can boost the overall T cell response and help to shrink tumors in mice. The study identifies specific neoantigens that, when targeted with a vaccine, can reawaken dormant T cell populations and lead to tumor regression.
A national study of 75,000 US adults found a near 18 percentage point increase in those willing to get vaccinated, but also a rise in skepticism among certain groups. Disparities persist in vaccine confidence, particularly among younger adults, non-Hispanic Black or multiple races, and lower socioeconomic status.
Project 2VIDA! aims to increase access and use of COVID-19 vaccines in San Diego's most heavily affected neighborhoods. The program directly educates the public on vaccine safety and addresses health disparities through a door-to-door outreach approach.
A study found that people who form antibodies against the folded receptor binding domain (RBD) of the SARS-CoV-2 spike protein are protected from infection. However, 20% of those who recovered from Covid-19 fail to develop these antibodies.
Researchers created a model to estimate viral population variability using epidemiological data, predicting the emergence of novel variants. The study suggests that lack of vaccination increases mutation frequency and spread.
Researchers identified and contacted patients with cancer who could benefit from targeted nonelectronic communication regarding COVID-19 immunization. The study used an analytics-based approach to reach marginalized populations, highlighting the importance of targeted outreach in increasing vaccine uptake.
Researchers at WashU Medicine have identified two antibodies that protect animals from disease caused by alphaviruses, which could form the basis of treatments or serve as a template for a universal vaccine. The antibodies worked against all tested alphaviruses and prevented arthritis and brain infections in animals.
A new study found that vaccinated SARS survivors can produce antibodies capable of neutralizing not only current but also future coronavirus threats. The breakthrough could lead to the development of an effective, broad-spectrum vaccine against different coronaviruses.
A multidisciplinary team reveals two structural points in the Spike protein of SARS-CoV-2 that allow the virus to deceive the immune system. These mutations can be detected and inform strategies to control the pandemic.
Researchers found that some medications used to treat autoimmune rheumatic diseases can weaken the immune response to COVID-19 vaccines. Vaccination still induced an immune response in patients, but at a lower rate than in those without autoimmune diseases.
Researchers developed a protein-based COVID-19 vaccine that mimics the SARS-CoV-2 virus shape, eliciting both antibody and T cell responses. The vaccine, using polymersomes decorated with multiple copies of the receptor binding domain antigen, shows promise for longer-lasting immunity.
A Dartmouth research team led by Glyn Elwyn is testing interactive educational approaches to boost vaccine confidence among unvaccinated long-term care workers. The study aims to measure vaccine confidence, knowledge, and trust in the COVID-19 vaccines.
Researchers found that targeted behavioral science messages significantly increased COVID-19 vaccination registration among healthcare workers. The study showed a substantial increase in vaccine uptake after receiving personalized email nudges.
Scientists have identified a promising vaccine target for animal African trypanosomiasis (AAT), a disease causing significant economic impact on livestock in Africa and South America. The vaccine candidate showed long-lasting protection against infection in mice, offering a potential solution to the devastating effects of AAT.
A study by University of California, Davis researchers found that prioritizing vaccination for vulnerable populations like seniors and essential workers can reduce deaths, infections, and years of life lost by 17-44%. The optimal strategy depends on the outbreak conditions, including vaccine supply and transmission rates.
A recent study published in Cell shows that SARS-CoV-2 mutations can evade both naturally occurring antibodies from COVID-19 survivors and lab-made antibodies now in clinical use. The research highlights the importance of designing next-generation vaccines and therapies that target less mutable parts of the virus.
A new study describes a vaccine that triggers an immune response against an influenza protein segment rarely mutated by the virus, raising the possibility of effective protection against seasonal and pandemic strains. The vaccine uses nanoparticles coated with flu proteins to train the immune system to create desired antibodies.
A new vaccine targeting HER2-positive breast cancers has been shown to work effectively in combination with immune checkpoint inhibitors, resulting in pronounced tumor reduction and long-term tumor-free survival. The study found that the vaccine primes the immune system, allowing the checkpoint inhibitor to rally T-cells to action.
A new analysis found that Russian trolls used fake persona types to discuss vaccination on Twitter during the 2016 US election cycle. The researchers identified nine types of troll personas and found that they targeted specific political groups with pro- and anti-vaccination messages.
Researchers examined over 500 vaccine-related ads on Facebook and found that a small group of anti-vaccine ad buyers targeted specific audiences, while pro-vaccination ads were often rejected due to Facebook's policies. The study highlights the need for social media platforms to balance free speech with public health concerns.
Researchers detected oral HPV DNA in 6.2% of teen and young adult female participants, with detection decreasing over time since becoming sexually active. The study suggests that the HPV vaccine is less effective against certain types of oral HPV in vaccinated individuals compared to those who are fully unvaccinated.
Researchers have developed a new type of vaccine targeting tuberculosis, providing substantial protection against the deadly disease. The early-stage vaccine was shown to be effective in pre-clinical laboratory settings and demonstrated its ability to stimulate the immune response in the lungs.
The University of Montana has received a $3.3 million contract from the National Institutes of Health to develop an opioid addiction vaccine. The vaccine targets fentanyl and prevents it from crossing the blood-brain barrier, offering a promising safe and cost-effective strategy to treat opioid use disorders.
Scientists have developed a new single vaccination approach that simultaneously protects against both influenza and pneumococcal infections, overcoming the limitations of current vaccines. The approach combines vaccines targeting different components of the virus and bacteria, inducing enhanced cross-protective immunity.